AbbVie Says Buying Spree Will Add R&D Heft Needed For Long-Term Growth
Cerevel Acquisition For $8.7bn Closely Follows $10.1bn ImmunoGen Buyout
Buying Cerevel six days after the ImmunoGen takeout, with a combined value of nearly $19bn, AbbVie thinks it has restocked its pipeline with future blockbusters to drive post-Humira growth.
